{'fraction_non_alphanumeric': 0.03876852907639681, 'fraction_numerical': 0.021664766248574687, 'mean_word_length': 5.223404255319149, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Secondary aortic valve replacement in continuous flow left ventricular assist device therapy.

AIM
The purpose of the study was to investigate the outcome of secondary surgical aortic valve replacement (sSAVR) in patients with severe aortic regurgitation (AR) in the context of ventricular assist device (VAD) therapy.


METHODS
From 2009 to 2020, 792 patients underwent cf-LVAD implantation [HVAD (Medtronic, USA), n=585, and HM 3 (Abbott, USA), n=207]. All cf-LVAD patients with severe AR requiring secondary AVR were enrolled in this study.


RESULTS
A total of six patients (median, 40 years, IQR; 34-61 years, 50% male) underwent secondary surgical aortic valve replacement (sSAVR) after cf-LVAD implantation. Median time of previous LVAD support was 26 months (IQR: 21-29 months). Two patients required additional tricuspid valve repair (TVR) and one patient underwent SAVR after failed TAVR. Four patients needed temporary right ventricular assist device (RVAD) with a median of 30 days (IQR; 29-33 days). Three patients were bridged to urgent heart transplantation due to persevering right heart failure, whereas two destination therapy (DT) candidates survived without any associated complications. An additional DT patient died of pneumonia one month after sSAVR.


CONCLUSIONS
Secondary surgical aortic valve replacement in ongoing LVAD patients is an advanced procedure for a complex cohort. In our series, sSAVR was safely performed and effective, but involved a high-risk for subsequent right heart failure, requiring urgent heart transplantation. In LVAD patients with severe AR requiring treatment TAVR is not feasible, sSAVR can be evaluated as salvage option for bridge-to-transplant patients or selected destination therapy candidates.